Targeted inactivation of EPS8 using dendrimer-mediated delivery of RNA interference.

We developed polyamidoamine dendrimers conjugated with epidermal growth factor (EGF) for use in receptor-mediated delivery of therapeutics to cancer cells. Here, we demonstrate the utility of this approach to inhibit proliferation and migration of head and neck squamous carcinoma cells through targeting of EPS8, a key regulator of squamous carcinoma growth and motility. Use of EGF-dendrimers to deliver siRNA or shRNA against EPS8 resulted in inhibition of cell growth and reduction in cell motility.

CYP1A1 is a target of miR-892a-mediated post-transcriptional repression.

Cytochrome P450 1A1 (CYP1A1) is a member of the cytochrome p450 enzyme family, which is involved in the metabolisms of carcinogenic metabolites, such as benzo(a)pyrene. In this study, we identified miR-892a as a negative regulator of CYP1A1 expression. Luciferase assays revealed a sequence in the 3'-untranslated region of CYP1A1 that displayed a perfect match with miR-892a, and revealed that this sequence was a specific miR-892a target site.

Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells.

Resveratrol is a plant phenolic phytoalexin that has been reported to have antitumor properties in several types of cancers. In particular, several studies have suggested that resveratrol exerts antiproliferative effects against A549 human non-small cell lung cancer cells; however, its mechanism of action remains incompletely understood. Deregulation of microRNAs (miRNAs), a class of small, noncoding, regulatory RNA molecules involved in gene expression, is strongly correlated with lung cancer.

Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery.

We designed an epidermal growth factor (EGF)-containing polyamidoamine (PAMAM) Generation 4 dendrimer vector labeled with quantum dots for targeted imaging and nucleic acid delivery. (1)H NMR, SDS-PAGE, and Western blotting were applied to characterize the synthesized G4.0-GGG-EGF nanoparticles.

MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.

MicroRNAs (miRNAs) are important post-transcriptional regulators involved in many biological processes. We investigated the expression profiles of miRNAs affected by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), and p53 in the human colon cancer cell line, HCT116 (wt-p53) and its derivative, HCT116 (null-p53). In a microarray assay, 144 of 275 human miRNAs showed several-fold changes in transcription.

Alteration of miRNA profiles by ionizing radiation in A549 human non-small cell lung cancer cells.

Ionizing radiation (IR) is widely used in cancer treatment and in biological studies. It disrupts cellular homeostasis through multiple mechanisms including changes of the expression profile of genes. Although microRNAs (miRNAs) have recently been recognized as important post-transcriptional regulators and are involved in various biological processes, whether miRNAs play any roles in the cellular response to IR, is not well examined.

Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.

Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase inhibitor (HDACI) with antitumor effects that is being explored as a therapeutic drug. However, it has been reported that non-small cell lung cancer (NSCLC) is resistant to HDACIs. MicroRNAs (miRNAs) are a key class of small, non-coding RNA molecules that modulate post-transcriptional regulation of gene expression in multi-cellular organisms.

Identification of ionizing radiation-responsive microRNAs in the IM9 human B lymphoblastic cell line.

Ionizing radiation (IR) disrupts cellular homeostasis through multiple mechanisms including changes of the expression profile of genes. Although microRNAs (miRNAs), small single-stranded RNAs, have recently been recognized as important post-transcriptional regulators of gene expression, it is not well investigated if miRNAs function in the cellular response to radiation. Therefore, we determined if IR induces changes in the expression profiles of miRNAs and used this approach to identify IR-responsive miRNAs.

MicroRNAs are significantly influenced by p53 and radiation in HCT116 human colon carcinoma cells.

Ionizing radiation is genotoxic to the cell, and p53 is commonly considered to be a key regulator that controls gene expression responding to the genotoxity of radiation. The expression profiles of microRNAs (miRNAs), which are small non-coding RNAs regulating the translation of target mRNAs, were analyzed to determine whether any correlation exists between miRNA expression, radiation response, and/or p53. The miRNA profiles were analyzed by microarray containing 470 human miRNA probes in HCT116 human colon carcinoma cells and their p53-null derivative.

Regional differences in the prevalence, treatment and control of hypertension and dyslipidemia in US urban Hispanic populations participating in health screening events.

Objective: We examine the prevalence, treatment, and control of hypertension, dyslipidemia, and concomitant hypertension and dyslipidemia among Hispanics in four US communities.

Methods: This was a cross-sectional study of Hispanics who participated in health screening programs from 2004 to 2006. We enrolled 5288 Hispanics in Miami (n=372), New York (n=254), Los Angeles (n=4037), and Houston (n=625).

Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia. Phase one was an 8-week, double-blind, double-dummy, placebo-controlled period whereby patients received amlodipine 5 mg, atorvastatin 10 mg, amlodipine 5 mg and atorvastatin 10 mg, or placebo. Thereafter, all patients received single-blind amlodipine 5 mg and atorvastatin 10 mg for 8-weeks, followed by 12 weeks of open-label treatment where doses could be titrated to improve low-density lipoprotein cholesterol and blood pressure control.